<font color="white">Molecular and Cellular Therapies</font> http://journals.riverpublishers.com/index.php/MCT <div class="JL3"> <div class="journalboxline"> <div class="JL3"> <div class="journalboxline"> <p><strong>Molecular and Cellular Therapies (MCT)</strong></p> <p>MCT is the frontline journal for molecular mechanisms, preclinical and clinical research and development of gene-, peptide-, protein-, and cell-based therapies, including target identification and validation, safety, toxicity, efficacy, efficiency, pharmacokinetics, metabolism, formulation, delivery, pharmacovigilance, biomarkers, new drug application. MCT, central to clinical and translational medicine, will integrate genetics, cell biology, medicine, drug development, therapeutics, and biotechnology to improve the prognosis of patients</p> </div> </div> </div> </div> <p>&nbsp;</p> River Publishers en-US <font color="white">Molecular and Cellular Therapies</font> 1904-4720 <p><strong>Copyright</strong><br>Copyright on any open access article in Molecular and Cellular Therapies published bythe Institute is retained by the author(s). Authors can grant any third party the right to use<br>the article freely as long as its integrity is maintained and its original authors, citation&nbsp; details and publisher are identified. Please contact the Office of Molecular and Cellular<br>Therapies for more information specifically regarding permissions if there are questions.</p> HIV Apheresis Tags (HIVAT) Aided Elimination of Viremia http://journals.riverpublishers.com/index.php/MCT/article/view/3 <div class="JL3"> <div class="jarticlebox"> <div id="hidden1463"><span style="font-family: Arial, Helvetica, sans-serif;"><strong>Abstract:</strong>&nbsp;HIV viremia is the essential element for progression of an initial HIV infection into AIDS and death. The currently approved management relies primarily on chemotherapy repressing the HIV replication in the infected CD4+ cells, although with severe systemic adverse effects. The problem is that it does not physically eliminate viruses, which then not only keep infecting healthy cells of these patients, but also promote infectivions of other people.</span></div> </div> </div> <p>&nbsp;</p> Marek Malecki Bianka Saetre ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-06-21 2018-06-21 1 15 10.26781/2052-8426-2018-06 HIV Universal Vaccine http://journals.riverpublishers.com/index.php/MCT/article/view/6 <div class="JL3"> <div class="jarticlebox"> <div id="hidden1462"><span style="font-family: Arial, Helvetica, sans-serif;"><strong>Abstract:</strong>&nbsp;For many deadly viruses, there are no preventive and / or therapeutic vaccines approved by health authorities World-wide (e.g., HIV, Ebola, Dengue, and many others). Although, for some viruses, prophylactic vaccines are very effective (e.g., HBV, Polio, Rota, and many others). In this realm, we design, manufacture, test, and streamline into the clinics novel viral universal vaccines (VUV). VUV have such unique features, that medical vaccination or natural infection induced immunity against some viruses (e.g., HBV) in patients, who became infected with other viruses (e.g., HIV), upon the VUV’s administration , is redirected against these other, newly infecting viruses (e.g., HIV).</span></div> </div> </div> <p>&nbsp;</p> Marek Malecki Bianka Saetre ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-11-06 2018-11-06 1 14 10.26781/2052-8426-2018-05 Effects of phosphoinositide 3-kinase inhibitor SHBM1009 on cancer cells proliferation http://journals.riverpublishers.com/index.php/MCT/article/view/9 <div class="JL3"> <div class="jarticlebox"> <div id="hidden1470"><span style="font-family: Arial, Helvetica, sans-serif;"><strong>Abstract:</strong>&nbsp;Phosphoinositide 3-kinase (PI3K) plays an important role in cellular proliferation and tumor progression. The objective of this study is to evaluate the potential mechanism and therapeutic effects of new PI3K inhibitor SHBM1009 on various cancer cells of digestive system on proliferation.</span></div> </div> </div> <p>&nbsp;</p> Dujiao Wu LiHao Huang Qi Shen Bijun Zhu ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-07-01 2018-07-01 1 7 10.26781/2052-8426-2018-04 RIPK1 and RIPK3 – emerging targets in cancer? http://journals.riverpublishers.com/index.php/MCT/article/view/11 <div class="JL3"> <div class="jarticlebox"> <div id="hidden1461"><span style="font-family: Arial, Helvetica, sans-serif;"><strong>Abstract:</strong>&nbsp;RIPK1 and RIPK3 are homologous Ser/Thr kinases, which act in concert within the necrosome complexes to initiate a sub-type of regulated necrosis, termed necroptosis. Necroptosis has gradually emerged as a highly clinically relevant form of necrosis, which can be targeted therapeutically. Besides necroptosis, RIPK1 and RIPK3 have been implicated in other pathophysiologically-relevant responses, including regulation of apoptosis and inflammation. More recently, it became evident that RIPK1/RIPK3 pathways may be systematically altered in cancers. Status of these pathways may provide a prognostic value, and therapeutic modulation of RIPK1/RIPK3 signaling may represent a new strategy against various forms of human cancer.</span></div> </div> </div> <p>&nbsp;</p> Kerem Gurol Suraj Shah Alexei Degterev ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-11-08 2018-11-08 1 13 10.26781/2052-8426-2018-03 Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS) http://journals.riverpublishers.com/index.php/MCT/article/view/12 <div class="JL3"> <div class="jarticlebox"> <div id="hidden1460"><span style="font-family: Arial, Helvetica, sans-serif;"><strong>Abstract:</strong>&nbsp;In patients suffering from breast cancer, adjuvant radiation, chemotherapy, or immunotherapy, which immediately follow the surgery as the first line therapy, greatly improve overall (OS) and disease-free survival (DFS). Various regimens of adjuvant therapy for these patients have been tested contingent upon the clinical staging. Inclusion of adjuvant immunotherapy is particularly promising.</span></div> </div> </div> <p>&nbsp;</p> Beata Jagielska Andrzej Czubek Konrad Talasiewicz Adam Twarowski Piotr Rutkowski Maciej Krzakowski Bianka Kathryn Saetre Marek Malecki ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-08-01 2018-08-01 1 12 10.26781/2052-8426-2018-02 The role of mitochondria-targeted antioxidant MitoQ in neurodegenerative disease http://journals.riverpublishers.com/index.php/MCT/article/view/13 <div class="JL3"> <div class="jarticlebox"> <div id="hidden1459"><span style="font-family: Arial, Helvetica, sans-serif;"><strong>Abstract:</strong>&nbsp;The discovery of charged molecules being able to cross the mitochondrial membrane has prompted many scholars to exploit this idea to find a way of preventing or slowing down aging. In this paper, we will focus on mitochondriatargeted antioxidants, which are cationic derivatives of plastoquinone, and in particular on the mitochondria-targeted antioxidant therapy of neurodegenerative diseases. It is well known that the accumulation of amyloid-β peptide (Aβ) in mitochondria and its related mitochondrial dysfunction are critical signatures of Alzheimer’ s disease (AD). In another neurodegenerative disease, Parkinson’s disease (PD), the loss of dopaminergic neurons in the substantia nigra and the production of Lewy bodies are among their pathological features. Pathogenesis of Parkinson’s disease and Alzheimer’s disease has been frequently linked to mitochondrial dysfunction and oxidative stress. Recent studies show that MitoQ, a mitochondria-targeted antioxidant, may possess therapeutic potential for Aβ-related and oxidative stress-associated neurodegenerative diseases, especially AD. Although MitoQ has been developed to the stage of clinical trials in PD, its true clinical effect still need further verification. This review aims to discuss the role of mitochondrial pathology in neurodegenerative diseases, as well as the recent development of mitochondrial targeted antioxidants as a potential treatment for these diseases by removing excess oxygen free radicals and inhibiting lipid peroxidation in order to improve mitochondrial function.</span></div> </div> </div> <p>&nbsp;</p> Linlin Zhang Aurelio Reyes Xiangdong Wang ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-09-01 2018-09-01 1 8 10.26781/2052-8426-2018-01